End Stage Renal Disease (ESRD) Drug Industry Analysis Report: Key Trends, Drivers, and Forecast Insights

 Ideal for market intelligence professionals and business strategists, this research uncovers where growth is headed in the end stage renal disease (esrd) drug industry.

How Large Will The End Stage Renal Disease (ESRD) Drug Market Be By 2025?
The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $131.41 billion in 2024 to $148.55 billion in 2025 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies.

The end stage renal disease (esrd) drug market size is expected to see rapid growth in the next few years. It will grow to $262.76 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, increasing healthcare expenditure, rising global burden of chronic kidney diseases, personalized medicine approaches, regulatory support, and expedited approvals. Major trends in the forecast period include increasing incidence of end stage renal disease, advancements in treatment modalities, growing emphasis on precision medicine, development of combination therapies, technological integration in healthcare.

Get your free sample today:
End Stage Renal Disease (ESRD) Drug Market Share Report 2025 Sample

What Are Key Factors Driving The Demand In The Global End Stage Renal Disease (ESRD) Drug Market?
Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improve blood sugar control. For instance, in March 2022, according to World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, the number of obese people is expected to rise to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in February 2023, according to the National Health Service, UK-based publicly funded healthcare system, It is estimated that by 2030, the number of people in the UK with diabetes could reach 5.5 million, impacting nearly 9% of the population. Therefore, the rising cases of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.

Comparative Analysis Of Leading End Stage Renal Disease (ESRD) Drug Market Segments
The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

What Are The Key Trends Shaping The End Stage Renal Disease (ESRD) Drug Industry?
Product innovations are a key trend in gaining popularity in the end-stage renal disease (ESRD) drug market. Major companies operating in the end-stage renal disease (ESRD) drug market are focused on developing innovative solutions to sustain in the market. For instance, in April 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the possible treatment of patients with chronic kidney disease anemia (CKD). The new product is based on the unique Nobel prize-winning science that proved how cells sense and adapt to oxygen availability.

Who Are The Prominent Players In The End Stage Renal Disease (ESRD) Drug Business?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

View the full end stage renal disease (esrd) drug market report here:
End Stage Renal Disease (ESRD) Drug Market Share Report 2025

Which Region Is Expected To Lead The End Stage Renal Disease (ESRD) Drug Market By 2025?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

#Contact Us:#

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


#Follow Us On:#

LinkedIn: The Business Research Company | LinkedIn